Egalet is a pharmaceutical company developing, manufacturing and commercializing treatment for pain and other conditions. Co. has two pain products, SPRIX® (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only-CII, to treat pain. Using its proprietary Guardian Technology, Co. has two product candidates in development; ARYMO ER (morphine sulfate) extended-release (ER), an ER morphine product formulated with abuse-deterrent (AD) properties, and Egalet-002, an AD, ER, oral oxycodone formulation, which is in a Phase 3 program. Also, Co. has Egalet-003, an AD stimulant product candidate, and Egalet-004, an AD, ER hydrocodone-based product candidate. The EGLT average annual return 10 years is shown above.
The Average Annual Return on the EGLT average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether EGLT average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the EGLT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|